Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

Analyst Ratings

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.75 (222.10% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Piper Jaffray Cos.Reiterated RatingOverweight$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016WedbushReiterated RatingOutperform$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Bank of America Corp.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Credit Suisse Group AGLower Price TargetOutperform$44.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/3/2016        
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.28)($0.28)($0.28)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.41)($0.41)($0.41)
Q4 20161($0.46)($0.46)($0.46)
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.48)($0.48)($0.48)
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.52)($0.52)($0.52)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aimmune Therapeutics (NASDAQ:AIMT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
DateHeadline
07/22/16 07:24 PMAimmune Therapeutics Inc Can't Burn Your Long Portfolio. Has Another Strong Session - Consumer Eagle
07/22/16 02:22 PMAimmune Therapeutics Inc Gaps Up; Strong Momentum for Buyers - Consumer Eagle
07/21/16 02:22 PMStock Moving Lower for the Month; Investor Update on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily
07/21/16 02:22 PMAimmune Therapeutics Inc's Stock Is Buy After Today's Huge Increase - Consumer Eagle
07/19/16 02:24 PMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 23.82% After Market Selling - Consumer Eagle
07/16/16 02:22 PMIncreased Volatility Noted on Shares of: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily
07/16/16 02:22 PMIncreased Volatility Noted on Shares of: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily
07/16/16 02:22 PMHow Many Aimmune Therapeutics Inc (NASDAQ:AIMT)'s Analysts Are Bullish? - Consumer Eagle
07/16/16 02:22 PMHow Many Aimmune Therapeutics Inc (NASDAQ:AIMT)'s Analysts Are Bullish? - Consumer Eagle
07/16/16 02:22 PMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 2.16% After Market Selling - Consumer Eagle
07/16/16 02:22 PMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 2.16% After Market Selling - Consumer Eagle
07/14/16 11:18 AMShares Losing Ground for the Month; Investor Alert on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily
07/14/16 11:18 AMEye on Stock Volatility for: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily
07/13/16 10:28 AMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Sellers Increased By 2.16% Their Shorts - Consumer Eagle
07/11/16 07:11 AMAimmune Therapeutics, Inc. (NASDAQ:AIMT) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 02:22 PMAimmune Therapeutics Incorporated (NASDAQ:AIMT) Short Interest Increased By 2.16% - Press Telegraph
07/08/16 10:26 AMHealthcare New Lows: Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Great Basin Scientific, Inc. (NASDAQ:GBSN ... - KC Register
07/08/16 10:26 AMHow Analysts Feel About Aimmune Therapeutics Inc (NASDAQ:AIMT)? - Press Telegraph
07/06/16 07:11 AMAimmune Therapeutics, Inc. (NASDAQ:AIMT) Current Analyst Ratings - Fiscal Standard
07/05/16 07:00 AMAimmune Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [Business Wire] - Aimmune Therapeutics, Inc. , a biopharmaceutical company developing CODIT™ treatments for life-threatening food allergies, today announced that Mary Rozenman, Ph.D., Senior Vice President of Corporate Development and Strategy at Aimmune, will present a company overview at Cantor Fitzgerald’s 2nd Annual Healthcare Conference in New York City, on Tuesday, July 12, 2016, at 3:30 p.m.
07/02/16 10:05 AMCompany Stock Lower on the Week Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily
07/01/16 02:24 PMMarket Movers: Aimmune Therapeutics (NASDAQ:AIMT), Insmed Incorporated (NASDAQ:INSM), Infoblox Inc. (NYSE ... - KC Register
07/01/16 02:24 PMHow Analysts Rated Aimmune Therapeutics Inc (NASDAQ:AIMT) Last Week? - Engelwood Daily
06/28/16 02:38 PMSmall Cap New Lows: Aimmune Therapeutics. (NASDAQ:AIMT), Waddell & Reed Financial, Inc. (NYSE:WDR ... - KC Register
06/27/16 07:09 AMNext Weeks Broker Price Targets For Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Fiscal Standard
06/24/16 02:23 PMAimmune Therapeutics, Inc. (NASDAQ:AIMT) Updated Price Targets - FTSE News
06/24/16 02:23 PMAimmune Therapeutics, Inc. (AIMT) Reached a 52-Week Low - Finance Daily
06/21/16 03:06 PMAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events -
06/21/16 07:09 AMAimmune Therapeutics (AIMT) Names Daniel Adelman M.D. as Chief Medical Officer - StreetInsider.com
06/21/16 06:19 AMAimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer - [at noodls] - - New CMO Is a Seasoned Clinical Development Leader and Food Allergy and Immunology Expert - BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 21, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical ...
06/20/16 08:53 AMAnalyst Views For The Week Ahead: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Fiscal Standard
06/16/16 02:23 PMAimmune Therapeutics, Inc. (AIMT) Trades at 52-Week Low - Finance Daily
06/13/16 03:00 PMAimmune Therapeutics Inc Management Conference Call on Late-Breaker Presentation at the EAACI scheduled for 4:00 pm ET today -
06/13/16 02:23 PMAimmune Therapeutics (AIMT) Announces New Data on AR101 Phase 2; Low-Dose Regimen Supported - StreetInsider.com
06/13/16 10:00 AMAimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy - [Business Wire] - Aimmune Therapeutics, Inc. , a biopharmaceutical company developing CODIT™ treatments for life-threatening food allergies, today announced that new Phase 2 extended maintenance therapy data from Aimmune’s lead product, AR101 for peanut allergy, showed that the safety and tolerability profile improved with continued treatment, particularly in a low-dose extended maintenance regimen.
06/10/16 04:18 PMLifeSci Capital Initiates Coverage of Aimmune Therapeutics - [Accesswire] - Developing the Oral Immunotherapy AR101 for Desensitization of Peanut Allergies; Report Available here: http://www.lifescicapital.com/equity-research/aimmune/ NEW YORK, NY / ACCESSWIRE / June 10, 2016 ...
06/07/16 10:47 AMAimmune Therapeutics (AIMT) Will Make AR101 Late- Breaker Presentation at EAACI Congress - StreetInsider.com
06/07/16 07:18 AMAimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 - [at noodls] - - Dr. Rima Rachid Will Present Data on the Safety and Tolerability of AR101 for Peanut Allergy after More than One Year of Treatment - - Management Will Host Conference Call on Monday, June 13, 2016, at ...
06/03/16 02:25 PMAimmune Therapeutics Inc (AIMT) Stock Price Down 6.3% Following Insider Selling - Let Me Know About This
06/02/16 08:21 PM240000 Shares of Stock are sold by Insider Selling: Aimmune Therapeutics Inc (AIMT) Major Shareholder - Let Me Know About This - 240000 Shares of Stock are sold by Insider Selling: Aimmune Therapeutics Inc (AIMT) Major ShareholderLet Me Know About ThisAimmune Therapeutics logo Aimmune Therapeutics Inc (NASDAQ:AIMT) major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the firm's stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a ...Analyst Review: Aimmune Therapeutics, Inc. (NASDAQ:AIMT)Risers & FallersWere Analysts Bullish Aimmune Therapeutics Inc (NASDAQ:AIMT) This Week?The Postall 4 news articles »
06/02/16 11:01 AMPrima Biomed (NASDAQ:PBMD) Went Down -0.93%: Aimmune Therapeutics (NASDAQ:AIMT), Old Republic ... - KC Register - Prima Biomed (NASDAQ:PBMD) Went Down -0.93%: Aimmune Therapeutics (NASDAQ:AIMT), Old Republic ...KC RegisterAimmune Therapeutics, Inc. (NASDAQ:AIMT) announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief Executive Officer of Aimmune, will present a company overview at two upcoming investor conferences in June as: Goldman Sachs 37th Annual Global ...and more »
06/01/16 04:04 PMAimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 04:02 PMAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events -
05/31/16 07:22 AMAimmune Therapeutics to Present at Upcoming June Investor Conferences - [at noodls] - BRISBANE, Calif.--(BUSINESS WIRE)--May 31, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for ...
05/28/16 12:00 PMHC Stocks Assessment: Aimmune Therapeutics (AIMT), Mazor Robotics (MZOR) - share market updates (press release) - HC Stocks Assessment: Aimmune Therapeutics (AIMT), Mazor Robotics (MZOR)share market updates (press release)Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) ended Wednesday session in green amid volatile trading. The shares closed up +1.07 points or 7.47% at $15.40 with 285,035.00 shares getting traded. Post opening the session at $14.35, the shares hit ...and more »
05/27/16 08:14 AMCan The Uptrend Continue for Aimmune Therapeutics (AIMT)? -
05/26/16 12:06 PMAimmune Therapeutics Inc Formed a Wedge Down Chart Pattern, Could Be One of The Worst Performers Going Forward - Wall Street Hints and News - Aimmune Therapeutics Inc Formed a Wedge Down Chart Pattern, Could Be One of The Worst Performers Going ForwardWall Street Hints and NewsThe stock of Aimmune Therapeutics Inc (AIMT) formed a down wedge with $14.63 target or 5.00% below today's $15.40 share price. The 7 months wedge indicates high risk for the $656.57 million company. If the $14.63 price target is reached, the company ...
05/23/16 12:28 PMRevenue Update on Aimmune Therapeutics Inc(NASDAQ:AIMT) - Trade Calls - Revenue Update on Aimmune Therapeutics Inc(NASDAQ:AIMT)Trade CallsAimmune Therapeutics Inc(NASDAQ:AIMT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 16, 2016. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.40. In a different note, ...and more »
05/16/16 03:22 PMAimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for ...
05/16/16 03:21 PMAimmune Therapeutics reports 1Q loss -

Social

About Aimmune Therapeutics

Aimmune Therapeutics logoAimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company's Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. Its lead product, AR101, which has completed a Phase II study, is designed to treat peanut allergy. The Company's AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AIMT
  • CUSIP:
Key Metrics:
  • Previous Close: $11.39
  • 50 Day Moving Average: $11.96
  • 200 Day Moving Average: $14.14
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $495.13M
  • Current Year EPS Consensus Estimate: $-1.66 EPS
  • Next Year EPS Consensus Estimate: $-2.1 EPS
Additional Links:
Aimmune Therapeutics (NASDAQ:AIMT) Chart for Saturday, July, 23, 2016